These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

326 related articles for article (PubMed ID: 11817323)

  • 1. Nucleic acid vaccines: tasks and tactics.
    McKenzie BS; Corbett AJ; Brady JL; Dyer CM; Strugnell RA; Kent SJ; Kramer DR; Boyle JS; Lew AM
    Immunol Res; 2001; 24(3):225-44. PubMed ID: 11817323
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combinations of various CpG motifs cloned into plasmid backbone modulate and enhance protective immunity of viral replicon DNA anthrax vaccines.
    Yu YZ; Ma Y; Xu WH; Wang S; Sun ZW
    Med Microbiol Immunol; 2015 Aug; 204(4):481-91. PubMed ID: 25265876
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Three types of human CpG motifs differentially modulate and augment immunogenicity of nonviral and viral replicon DNA vaccines as built-in adjuvants.
    Yu YZ; Li N; Ma Y; Wang S; Yu WY; Sun ZW
    Eur J Immunol; 2013 Jan; 43(1):228-39. PubMed ID: 23037552
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adjuvant formulations and delivery systems for DNA vaccines.
    Sasaki S; Takeshita F; Xin KQ; Ishii N; Okuda K
    Methods; 2003 Nov; 31(3):243-54. PubMed ID: 14511957
    [TBL] [Abstract][Full Text] [Related]  

  • 5. DNA vaccines--challenges in delivery.
    Pachuk CJ; McCallus DE; Weiner DB; Satishchandran C
    Curr Opin Mol Ther; 2000 Apr; 2(2):188-98. PubMed ID: 11249641
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recent developments in adjuvants for vaccines against infectious diseases.
    O'Hagan DT; MacKichan ML; Singh M
    Biomol Eng; 2001 Oct; 18(3):69-85. PubMed ID: 11566599
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multivalent minigene vaccines against infectious disease.
    An LL; Whitton JL
    Curr Opin Mol Ther; 1999 Feb; 1(1):16-21. PubMed ID: 11249678
    [No Abstract]   [Full Text] [Related]  

  • 8. Immunology of DNA vaccines: CpG motifs and antigen presentation.
    Manders P; Thomas R
    Inflamm Res; 2000 May; 49(5):199-205. PubMed ID: 10893042
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CpG motifs for optimization of DNA vaccines.
    Davis HL
    Dev Biol (Basel); 2000; 104():165-9. PubMed ID: 11713816
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genetic adjuvants for DNA vaccines.
    Scheerlinck JY
    Vaccine; 2001 Mar; 19(17-19):2647-56. PubMed ID: 11257404
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Engineering enhancement of the immune response to HBV DNA vaccine in mice by the use of LIGHT gene adjuvant.
    Zhang Y; Jiang W; Fan Y; Wen J; Hao W; Qian M
    J Virol Methods; 2008 Nov; 153(2):142-8. PubMed ID: 18722475
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cytotoxic T-lymphocyte-, and helper T-lymphocyte-oriented DNA vaccination.
    Nagata T; Aoshi T; Uchijima M; Suzuki M; Koide Y
    DNA Cell Biol; 2004 Feb; 23(2):93-106. PubMed ID: 15000749
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Engineering of DNA vaccines using molecular adjuvant plasmids.
    Sin JI; Kim J; Chattergoon M; Ayyavoo V; McCallus D; Ugen KE; Boyer JD; Weiner DB
    Dev Biol (Basel); 2000; 104():187-98. PubMed ID: 11713819
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Potentiation of anthrax vaccines using protective antigen-expressing viral replicon vectors.
    Wang HC; An HJ; Yu YZ; Xu Q
    Immunol Lett; 2015 Feb; 163(2):206-13. PubMed ID: 25102364
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CpG motifs are efficient adjuvants for DNA cancer vaccines.
    Schneeberger A; Wagner C; Zemann A; Lührs P; Kutil R; Goos M; Stingl G; Wagner SN
    J Invest Dermatol; 2004 Aug; 123(2):371-9. PubMed ID: 15245438
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting the mucosa: genetically engineered vaccines and mucosal immune responses.
    Stevceva L; Abimiku AG; Franchini G
    Genes Immun; 2000 Jun; 1(5):308-15. PubMed ID: 11196691
    [TBL] [Abstract][Full Text] [Related]  

  • 17. DNA vaccination against tumors.
    Prud'homme GJ
    J Gene Med; 2005 Jan; 7(1):3-17. PubMed ID: 15538731
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Presence of CpG DNA and the local cytokine milieu determine the efficacy of suppressive DNA vaccination in experimental autoimmune encephalomyelitis.
    Lobell A; Weissert R; Eltayeb S; Svanholm C; Olsson T; Wigzell H
    J Immunol; 1999 Nov; 163(9):4754-62. PubMed ID: 10528174
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Enhancement of the immunogenicity of an alphavirus replicon-based DNA vaccine against classical swine fever by electroporation and coinjection with a plasmid expressing porcine interleukin 2.
    Tian DY; Sun Y; Wai SF; Lee FK; Meng QL; Suen KM; Wang N; Han W; Li S; Li YF; Li D; Ling LJ; Liao YJ; Qiu HJ
    Vaccine; 2012 May; 30(24):3587-94. PubMed ID: 22469861
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mucosal immunization with DNA vaccines.
    Hobson P; Barnfield C; Barnes A; Klavinskis LS
    Methods; 2003 Nov; 31(3):217-24. PubMed ID: 14511954
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.